Live coverage has ended. The full story is below.
Tilray Brands (NASDAQ: TLRY) reports fiscal Q1 2026 results before the market opens, following a transition year defined by consolidation and margin repair. The stock is up 275% over the past 6 months as investors look to see if the turnaround can keep momentum moving forward.
Last quarter’s print (Q4 FY2025) showed clear progress — EPS beat $0.02 vs. est. $0.00 — as international cannabis and spirits drove gross margin expansion. Yet shares finished down 5% after weaker beverage margins and cautious cash-flow trends.
This quarter’s release will test whether Tilray’s profitability narrative is sustainable amid muted cannabis volume and continued beverage rationalization.
Estimates Snapshot
| Metric |
Q1 FY2026 Estimate |
YoY Change |
FY2026 Estimate |
FY2027 Estimate |
| Revenue |
$205.75 M |
+2.9 % vs $200 M |
$863.47 M |
$901.79 M |
| EPS (Normalized) |
$0.00 |
+$0.01 vs –$0.01 prior year |
$0.04 |
–$0.07 |
| Analyst Range (FY26) |
$830.5 M – $891.5 M rev / $0.03 – $0.04 EPS |
|
|
|
Tilray has beaten EPS estimates four consecutive quarters, but top-line momentum remains constrained as the company trims low-margin SKUs and channels.
Consensus implies low-single-digit growth early in FY26, improving into the back half as Project 420 synergies ($33 M target) and AI-driven greenhouse automation start to flow through.
Key Areas To Watch
-
International Medical Cannabis Expansion – Germany and Poland were standouts in Q4, with +134% YoY German growth and new self-pay market entry. Investors expect continued EMEA gains under Managing Director Rajnish Ohri, who leads Tilray’s push into the Middle East & Asia.
-
Beverage & Project 420 Margins – Integration of SweetWater, Montauk, and Shock Top has depressed beverage margin (38% vs 53% YoY). The focus this quarter: sequential recovery as SKU optimization winds down and holiday distribution begins.
-
THC & Wellness Flywheel – Hemp-derived THC beverages now reach 1,300 U.S. retail points across 13 states, while HiBall Energy and Manitoba Harvest sustain mid-single-digit growth. Watch for early regulatory commentary on interstate THC distribution.
-
Canadian Cannabis Share Dynamics – After reclaiming the #1 flower slot in Q4 via Redecan & Broken Coast, any volume recovery would signal a turning point in Tilray’s domestic optimization strategy.
-
Cash & Leverage Profile – Last quarter’s free cash flow (–$121 M) and cash balance $256 M left Tilray’s net-debt-to-EBITDA at 0.3× — a manageable base but still sensitive to integration costs. Sustained EBITDA above $25 M would confirm a credible path toward the FY26 goal of $62–72 M.
Contact [email protected] for any questions or corrections.